PCSK9 inhibition after heart transplantation: how low does low-density lipoprotein cholesterol need to go for cardiac allograft vasculopathy prevention? [PDF]
J Thorac DisWeis M.
europepmc +1 more source
The effect of PCSK9 inhibitors on cardiovascular outcomes in diabetic patients: a narrative review. [PDF]
Front PharmacolKhalid Sharafeldin AB +4 more
europepmc +1 more source
Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]
JACC AdvBlais JE +4 more
europepmc +1 more source
Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. [PDF]
Rev Cardiovasc MedSabouret P, Giamundo DM, Mamas M.
europepmc +1 more source
PCSK9 inhibitors in neurodegenerative disorders: mechanisms, therapeutic potential, and clinical implications. [PDF]
Transl NeurodegenerWang JDJ +8 more
europepmc +1 more source
Quality Over Quantity: Targeting Lipoprotein(a) Beyond Circulating Levels. [PDF]
JACC Basic Transl SciTirandi A, Liberale L, Camici GG.
europepmc +1 more source
The Impact of PCSK9 Inhibitors on Circulatory Inflammation: Mechanisms, Evidence, and Application Prospects. [PDF]
JACC AsiaBing-Yan D +7 more
europepmc +1 more source
PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway. [PDF]
Int J Mol SciLin S, Wu B, Sun S, Sun T.
europepmc +1 more source
Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. [PDF]
Lipids Health DisKafol J +12 more
europepmc +1 more source
Therapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence. [PDF]
Front Endocrinol (Lausanne)Yang XH, Liu Y, Fu CS, Jin HM, Ye ZB.
europepmc +1 more source